# Suki AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suki-ai

- Industry: Healthcare IT
- Headquarters: Redwood City, US
- Website: www.suki.ai
- Total disclosed funding: $160M
- Latest round: Series D (Oct 10, 2024)
- Investors on record: 11

## About

Suki AI, Inc. is a US-based company that provides innovative solutions for enhancing documentation processes in healthcare, focusing on efficient workflows for clinicians through advanced AI technology.Suki AI, Inc. specializes in AI-driven solutions for healthcare documentation. Founded in 2017 in Redwood City, US, by Andre Ingvoldstad and Punit Soni, the company has engaged in 6 deals, with its latest funding round being a Series D of USD 64.966 mn led by Hedosophia on January 30, 2025, bringing the total amount raised to USD 64.966 mn and a current valuation of USD 254.380 mn.Suki AI offers a comprehensive suite of products designed to enhance the documentation process within healthcare settings. The core product, Suki, combines ambient documentation, dictation, coding, and question-answering capabilities into a single solution, enabling clinicians to streamline their workflow efficiently. This platform integrates seamlessly with Electronic Health Records (EHRs), allowing clinicians to prechart and complete notes, pull dynamic data, and send finalized notes back to the EHR without interruption. Suki's target clientele includes major health systems across the United States, which range from small practices with a handful of clinicians to vast networks employing tens of thousands. The technology supports clinicians in a variety of geographic markets, including urban centers and rural areas, ensuring broad accessibility to enhanced documentation tools.Suki AI operates on a subscription-based business model tailored for healthcare providers. Clients can engage in partnerships with Suki to implement their services, typically resulting in a mutually beneficial relationship focused on increasing operational efficiency and revenue generation for health systems. Through the use of Suki's integrated documentation solutions, clients can realize higher reimbursements and increase patient encounters, leading to positive returns on investment as early as two months after implementation. This revenue structure allows Suki to create long-term relationships with health systems, with ongoing support and services provided on a continuous basis. The company’s flagship product, which encompasses ambient documentation and AI dictation, plays a central role in the value proposition presented to clients, ensuring that healthcare providers maximize their investment in Suki’s technology.In January 2025, Suki AI, Inc. raised an undisclosed amount of venture funding from new investor Zoom Ventures. The company will use this funding to strengthen its partnership with Zoom and advance its AI capabilities for clinician solutions. Suki AI plans to expand into new markets and geographic regions, targeting specific areas that align with their growth strategy.

## Funding rounds

- Series D, Oct 10, 2024, $65M — Venrock, Breyer Capital, March Capital, Flare Capital Partners, Hedosophia, InHealth Ventures
- Series C, Dec 7, 2021, $55M — Venrock, Breyer Capital, March Capital, Gaingels, Flare Capital Partners, InHealth Ventures, Philips Health Technology Ventures
- Series B, Mar 4, 2020, $20M — Venrock, First Round Capital, Breyer Capital, Flare Capital Partners, Epsilon Health
- Series A, May 1, 2018, $15M — Venrock, First Round Capital, Social Capital
- Seed, Mar 2, 2016, $5M — Venrock

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Seed, Series A, Series B, Series C, Series D
- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Series A, Series B
- Social Capital (https://capitalatlas.ai/funds/social-capital) — Series A
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series B, Series C, Series D
- Flare Capital Partners (https://capitalatlas.ai/funds/flare-capital-partners) — Series B, Series C, Series D
- Epsilon Health — Series B
- March Capital (https://capitalatlas.ai/funds/march-capital) — Series C, Series D
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series C
- InHealth Ventures (https://capitalatlas.ai/funds/inhealth-ventures) — Series C, Series D
- Philips Health Technology Ventures (https://capitalatlas.ai/funds/philips-health-technology-ventures) — Series C
- Hedosophia (https://capitalatlas.ai/funds/hedosophia) — Series D